Navigation Links
Mylan Receives Approval for Generic Version of Effexor XR® Capsules
Date:6/2/2011

PITTSBURGH, June 2, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride (HCl) Extended-release (ER) Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR® Capsules, which are used in the treatment of major depressive disorder and social anxiety disorder. Mylan is launching these products through a previously announced settlement and license agreement entered into with Wyeth, which is now part of Pfizer.

Venlafaxine HCl ER Capsules had U.S. sales of approximately $2.3 billion for the 12 months ending March 31, 2011, according to IMS Health. The product is being shipped to customers.

Currently, Mylan has 164 ANDAs pending FDA approval representing $95.6 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Launches Generic Version of Roxicodone® Tablets
2. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
3. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
4. Mylan Launches First Generic Version of Amrix® Capsules
5. Mylan Launches Generic Version of Risperdal® M-Tab®
6. Mylan Launches First Generic Version of Femara® Tablets
7. Mylan Launches Generic Version of Famvir® Tablets
8. Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
9. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
10. Moodys Upgrades Mylan
11. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):